J. Coen Netelenbos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. Coen Netelenbos has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
P Lips
Academisch Ziekenhuis Vrije Universiteit, afd. Endocrinologie, Amsterdam
2 shared publications- Amber Awa van der Heijden
Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, The Netherlands
1 shared publication - Babette C. van der Zwaard
Department of Orthopedic Surgery, Jeroen Bosch Hospital, PO Box 90153, 5200 ME, 's-Hertogenbosch, The Netherlands.
1 shared publication - Behrouz Zandieh-Doulabi
Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, 1081 LA Amsterdam, The Netherlands
1 shared publication - Christy Niemeijer
Stichting Artsen Laboratorium en Trombosedienst, Koog Aan de Zaan, Zaanstad, The Netherlands
1 shared publication - Dimitra Micha
Department of Human Genetics, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 October 2017
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 18 (1) , 424
Design of the SALT Osteoporosis Study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older
Several drugs have become available for the treatment of osteoporosis. However, screening and treatment of patients with a high fracture risk is currently not recommended in the Netherlands, because the effectiveness of bone sparing drugs has not been demonstrated in the general primary care population. Here we describe the design of the SALT Osteoporosis study, which aims to examine whether the screening and treatment of older, female patients in primary care can reduce fractures, in comparison to usual care. A randomised pragmatic trial has been designed using a stepwise approach in general care practices in the Netherlands. Women aged ≥65 years, who are not prescribed bone sparing drugs or corticosteroids are eligible for the study. First, women with at least one clinical risk factor for fractures, as determined by questionnaires, are randomly assigned to the intervention or control group. Second, women in the intervention group having a high fracture risk according to our screening program, including an adapted fracture risk assessment (FRAX) tool, combined with dual-energy x-ray absorptiometry (DXA), and instant vertebral assessment (IVA), are offered a structured treatment program. The women in the control group receive care as usual and will undergo the same screening as the intervention group at the end of the trial. The follow-up duration will be three years and the primary outcome is time to first incident fracture and the total number of fractures. The results of the current study will be very important for underpinnings of the prevention strategy of the osteoporosis guidelines. ID NTR2430 . Registered 26 July 2010.
- 27 October 2017
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 18 (1) , 424
Open AccessDesign of the SALT Osteoporosis Study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older
Several drugs have become available for the treatment of osteoporosis. However, screening and treatment of patients with a high fracture risk is currently not recommended in the Netherlands, because the effectiveness of bone sparing drugs has not been demonstrated in the general primary care population. Here we describe the design of the SALT Osteoporosis study, which aims to examine whether the screening and treatment of older, female patients in primary care can reduce fractures, in comparison to usual care. A randomised pragmatic trial has been designed using a stepwise approach in general care practices in the Netherlands. Women aged ≥65 years, who are not prescribed bone sparing drugs or corticosteroids are eligible for the study. First, women with at least one clinical risk factor for fractures, as determined by questionnaires, are randomly assigned to the intervention or control group. Second, women in the intervention group having a high fracture risk according to our screening program, including an adapted fracture risk assessment (FRAX) tool, combined with dual-energy x-ray absorptiometry (DXA), and instant vertebral assessment (IVA), are offered a structured treatment program. The women in the control group receive care as usual and will undergo the same screening as the intervention group at the end of the trial. The follow-up duration will be three years and the primary outcome is time to first incident fracture and the total number of fractures. The results of the current study will be very important for underpinnings of the prevention strategy of the osteoporosis guidelines. ID NTR2430 . Registered 26 July 2010.
- Open Access
- 14 September 2010
- Published by Springer Nature in Osteoporosis International
- Vol. 22 (5) , 1537-1546
Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands
Summary We analyzed 12-month compliance for all ten oral osteoporosis drugs in the Netherlands by medication possession ratio (MPR ≥ 80%) in 105,506 patients, and persistence in 8,626 starters indicated high MPR (91%), low persistence (43%), and no restart in 78% of the stoppers after 18 months. Introduction We studied compliance and persistence for all available oral osteoporosis medications on a national scale in the Netherlands. Methods We analyzed the IMS Health’s longitudinal prescription database, which represents 73% of all pharmacies in the Netherlands. Twelve-month compliance was measured by medication possession ratio (MPR) in a cross-sectional cohort of 105,506 patients who received at least three prescriptions. Twelve-month persistence (no gap in refills for >6 months) was measured in all 8,626 consecutive patients starting therapy, with a further follow-up in non-persistent patients during an additional 18 months for evaluation of switching, restart, or definitive stopping oral medication. Multivariate logistic regression analysis was used to analyze the odds ratios (ORs) with 95% confidence intervals (CI) of characteristics of non-persistence. Results MPR of ≥80% was found in 91% of patients. Persistence was 43% (range, 29–52%). Persistence was related to age >60 years (ORs, 1.41 to 1.64), pharmacy outside very dense urban area (ORs, 1.39 to 1.44), additional use of calcium and/or vitamin D supplementation (OR, 1.26 and CI, 1.13, 1.39) and use of glucocorticoids (OR, 0.65 and CI, 0.59, 0.72) or cardiovascular medication (OR, 0.88 and CI, 0.79, 0.97). Of non-persistent patients, 22% restarted within 18 months with oral osteoporosis drugs. Conclusions One-year compliance for all available oral osteoporosis medications was high, but 1-year persistence was low. Most stoppers did not restart or switch during an additional 18-month follow-up. These data indicate a major failure to adequately treat patients at high risk for fractures in daily practice.
- 14 September 2010
- Published by Springer Nature in Osteoporosis International
- Vol. 22 (5) , 1537-1546
Open AccessAdherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands
Summary We analyzed 12-month compliance for all ten oral osteoporosis drugs in the Netherlands by medication possession ratio (MPR ≥ 80%) in 105,506 patients, and persistence in 8,626 starters indicated high MPR (91%), low persistence (43%), and no restart in 78% of the stoppers after 18 months. Introduction We studied compliance and persistence for all available oral osteoporosis medications on a national scale in the Netherlands. Methods We analyzed the IMS Health’s longitudinal prescription database, which represents 73% of all pharmacies in the Netherlands. Twelve-month compliance was measured by medication possession ratio (MPR) in a cross-sectional cohort of 105,506 patients who received at least three prescriptions. Twelve-month persistence (no gap in refills for >6 months) was measured in all 8,626 consecutive patients starting therapy, with a further follow-up in non-persistent patients during an additional 18 months for evaluation of switching, restart, or definitive stopping oral medication. Multivariate logistic regression analysis was used to analyze the odds ratios (ORs) with 95% confidence intervals (CI) of characteristics of non-persistence. Results MPR of ≥80% was found in 91% of patients. Persistence was 43% (range, 29–52%). Persistence was related to age >60 years (ORs, 1.41 to 1.64), pharmacy outside very dense urban area (ORs, 1.39 to 1.44), additional use of calcium and/or vitamin D supplementation (OR, 1.26 and CI, 1.13, 1.39) and use of glucocorticoids (OR, 0.65 and CI, 0.59, 0.72) or cardiovascular medication (OR, 0.88 and CI, 0.79, 0.97). Of non-persistent patients, 22% restarted within 18 months with oral osteoporosis drugs. Conclusions One-year compliance for all available oral osteoporosis medications was high, but 1-year persistence was low. Most stoppers did not restart or switch during an additional 18-month follow-up. These data indicate a major failure to adequately treat patients at high risk for fractures in daily practice.
- 1 January 1999
- Published by Springer Nature in Osteoporosis International
- Vol. 9 (6) , 489
Bone Histomorphometric Evaluation of Pamidronate Treatment in Clinically Manifest Osteoporosis
- 1 January 1999
- Published by Springer Nature in Osteoporosis International
- Vol. 9 (6) , 489
Bone Histomorphometric Evaluation of Pamidronate Treatment in Clinically Manifest Osteoporosis
- 8 June 1996
- Vol. 140 (23) , 1215-7
[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis].
- 8 June 1996
- Vol. 140 (23) , 1215-7
[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis].
- 1 December 1985
- Vol. 16 (6) , 239-45
[Vitamin D deficiency and hip fracture].
Vitamin D deficiency is common in the elderly, especially in patients with hip fracture. Elderly people infrequently stay outside in the sunshine, and nutrition is deficient in vitamin D. In addition, the hydroxylation of vitamin D into active metabolites decreases with age. Vitamin D deficiency ultimately leads to osteomalacia, but in an earlier stage it causes secondary hyperparathyroidism, which is accompanied by increased bone turnover and cortical bone loss. Along these pathways vitamin D deficiency may contribute to the pathogenesis of hip fractures. In a survey in Amsterdam vitamin D deficiency was observed in more than 60% of the patients with hip fracture. Transilial bone biopsy showed signs of high turnover and cortical bone loss in more than 20% of patients. The elderly which are institutionalized carry an increased risk. Prevention or vitamin D deficiency is possible by adequate exposure to ultraviolet light. Primarily, the elderly should be encouraged to go out into the sunshine regularly. Advice on nutrition may be given additionally. When sunshine exposure is negligible, as in many disabled and institutionalized elderly, a daily supplement of vitamin D3 400 IU should be given. Preventive measures have to be evaluated prospectively. Vitamin D deficiency is not the most important risk factors for hip fractures, but the easiest to correct.
- 1 December 1985
- Vol. 16 (6) , 239-45
[Vitamin D deficiency and hip fracture].
Vitamin D deficiency is common in the elderly, especially in patients with hip fracture. Elderly people infrequently stay outside in the sunshine, and nutrition is deficient in vitamin D. In addition, the hydroxylation of vitamin D into active metabolites decreases with age. Vitamin D deficiency ultimately leads to osteomalacia, but in an earlier stage it causes secondary hyperparathyroidism, which is accompanied by increased bone turnover and cortical bone loss. Along these pathways vitamin D deficiency may contribute to the pathogenesis of hip fractures. In a survey in Amsterdam vitamin D deficiency was observed in more than 60% of the patients with hip fracture. Transilial bone biopsy showed signs of high turnover and cortical bone loss in more than 20% of patients. The elderly which are institutionalized carry an increased risk. Prevention or vitamin D deficiency is possible by adequate exposure to ultraviolet light. Primarily, the elderly should be encouraged to go out into the sunshine regularly. Advice on nutrition may be given additionally. When sunshine exposure is negligible, as in many disabled and institutionalized elderly, a daily supplement of vitamin D3 400 IU should be given. Preventive measures have to be evaluated prospectively. Vitamin D deficiency is not the most important risk factors for hip fractures, but the easiest to correct.
- 1 October 1981
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 141 (11) , 1555-1556
Hyperparathyroidism After Radioactive Iodine Therapy
To the Editor. —In the February 1980 issue of the Archives (140:205-207), Rao et al report a series of patients with hyperparathyroidism (HPT) after head and neck irradiation with x-ray therapy. In the discussion, they mention the absence of reports on HPT after radioactive iodine (131 I) therapy. Tisell et al,1 however, in 1976, described a patient who experienced HPT nine years after 131I therapy for hyperthyroidism. Our series of 77 patients with HPT contains two patients who received sodium iodide I 131 therapy 11 and 20 years before diagnosis of HPT because of toxic nodular goiter. In these same series, there are ten other patients with HPT and foregoing x-ray irradiation for benign diseases in childhood or adolescence. Report of Cases. —Case 1.—An 80-year-old woman was treated 11 years previously with 8 mCi of sodium iodide I 131 because of toxic nodular goiter. She was admitted to
- 1 October 1981
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 141 (11) , 1555-1556
Hyperparathyroidism After Radioactive Iodine Therapy
To the Editor. —In the February 1980 issue of the Archives (140:205-207), Rao et al report a series of patients with hyperparathyroidism (HPT) after head and neck irradiation with x-ray therapy. In the discussion, they mention the absence of reports on HPT after radioactive iodine (131 I) therapy. Tisell et al,1 however, in 1976, described a patient who experienced HPT nine years after 131I therapy for hyperthyroidism. Our series of 77 patients with HPT contains two patients who received sodium iodide I 131 therapy 11 and 20 years before diagnosis of HPT because of toxic nodular goiter. In these same series, there are ten other patients with HPT and foregoing x-ray irradiation for benign diseases in childhood or adolescence. Report of Cases. —Case 1.—An 80-year-old woman was treated 11 years previously with 8 mCi of sodium iodide I 131 because of toxic nodular goiter. She was admitted to